Study | Year | Treatment | ORR | DCR | TRAE | Grade ≥ 3 TRAEs | ||
---|---|---|---|---|---|---|---|---|
No of response | No of patients | No of response | No of patients | |||||
RCTs of early-staged lung cancer | ||||||||
 checkmate159 [24] | 2021 | nivo | 2 | 22 | 20 | 22 | 23% | 4.5% |
 IFCT-1601 IONESCO [25] | 2017 | durva | 4 | 43 | 37 | 43 | NR | NR |
 NADIM [26] | 2020 | nivo+chemo | 36 | 46 | 44 | 46 | 93% | 30% |
 NEOSTAR [27] | 2020 | nivo | 5 | 23 | NR | 23 | NR | 13% |
nivo+ipi | 4 | 21 | NR | 21 | NR | 10% | ||
 SAKK16 14 [21] | 2021 | durva+chemo | 36 | 62 | 52 | 62 | NR | 88.1% |
 PRINCEPS | 2020 | atezo | 16 | 29 | NR | 29 | NR | NR |
 Checkmate-816 | 2021 | nivo+chemo | NR | NR | NR | NR | 41% | 11% |
 IMpower010 [20] | 2021 | atezo+chemo | NR | NR | NR | NR | 93% | 22% |
 Lcmc3 | 2021 | atezo | NR | NR | NR | NR | 67% | 16% |
RCTs of advanced lung cancer | ||||||||
 KEYNOTE-001 [28] | 2019 | perm | 143 | 550 | 490 | 550 | 71% | 12% |
 KEYNOTE-010 [29] | 2015 | perm-2mg/kg | 62 | 344 | NR | 344 | 63% | 13% |
perm-10mg/kg | 64 | 346 | NR | 346 | 66% | 16% | ||
 KEYNOTE-021 [14] | 2016 | perm | 33 | 60 | 53 | 60 | 94% | 40% |
 KEYNOTE-024 [30] | 2016 | perm | 69 | 154 | NR | 154 | 73.4% | 26.6% |
 KEYNOTE-042 [31] | 2019 | perm | 174 | 637 | 422 | 637 | 63% | 18% |
 CheckMate-026 [15] | 2017 | nivo | 55 | 211 | 135 | 211 | 71% | 18% |
 IMpower110 [7] | 2010 | atezo | 81 | 277 | NR | 277 | 90.2% | 30.1% |
 OAK [11] | 2016 | atezo | 108 | 622 | 208 | 425 | 64% | 15% |
 poplar [10] | 2016 | atezo | 96 | 144 | NR | 144 | 67% | 40% |
 IMpower130 [9] | 2019 | atezo+chemo | 220 | 447 | 256 | 447 | 96.1% | 74.8% |
 IMpower131 [8] | 2020 | atezo+chemo | 170 | 342 | 277 | 342 | 94.6% | 69.2% |
 IMpower132 [5] | 2020 | atezo+chemo | 137 | 292 | NR | 292 | 91.4% | 58.4% |
 KEYNOTE-189 [32] | 2020 | atezo+chemo | 195 | 410 | 347 | 410 | 99.8% | 67.2% |
 KEYNOTE-407 [6] | 2020 | atezo+chemo | 174 | 278 | 239 | 278 | 98.6% | 74.1% |
 Camel [13] | 2020 | camre | 111 | 205 | NR | 205 | 99.5% | 68.8% |
 Camel-sq | 2021 | camre | 125 | 193 | 170 | 193 | 100% | 80.3% |
 Empower-lung1 [4] | 2021 | cemip | 111 | 283 | 187 | 283 | 57% | 14% |
 JAVELIN Lung 200 [12] | 2018 | ave | 50 | 264 | 136 | 264 | 64% | 10% |
 MYSTIC [33] | 2020 | durva | 66 | 286 | NR | 286 | 54.2% | 14.9% |
durva+chemo | 65 | 268 | NR | 268 | 60.1% | 22.9% | ||
 ORIENT-11 [17] | 2020 | sinti+chemo | 138 | 266 | NR | 266 | 99.6% | 61.7% |
 ORIENT-12 [34] | 2021 | sinti+chemo | 80 | 179 | NR | 179 | 100% | 86.6% |
 RATIONAL-304 [19] | 2021 | tisle | 128 | 233 | NR | 233 | 100% | 33.3% |
 RATIONAL-307 [18] | 2021 | tisle+pc | 87 | 120 | 105 | 120 | 99.2% | 85.8% |
tisle+nab-pc | 89 | 119 | 108 | 119 | 99.2% | 83.9% | ||
 CheckMate 012 [35] | 2017 | nivo+ipi(12w) | 18 | 38 | 30 | 38 | 82% | 37% |
nivo+ipi (6w) | 15 | 39 | 22 | 39 | 71% | 33% | ||
 CheckMate 017 [36] | 2015 | nivo | 27 | 135 | 66 | 135 | 58% | 7% |
 CheckMate 057 [37] | 2015 | nivo | 56 | 292 | 130 | 292 | 69% | 10% |
 KEYNOTE-025 [16] | 2018 | perm | 8 | 37 | 20 | 37 | 87% | 29% |
 CheckMate 063 [38] | 2015 | nivo | 17 | 117 | 47 | 117 | 74% | 17% |
 CheckMate 078 [39] | 2018 | nivo | 56 | 338 | 177 | 338 | 64% | 10% |
 IMpower150 [40] | 2019 | atez+beva+chemo | 224 | 397 | 335 | 397 | NR | 67% |
atez+chemo | 163 | 401 | 317 | 401 | NR | 61% | ||
 ARCTIC [41] | 2020 | durva | 22 | 62 |  | 62 | 96.8% | 40.3% |
 CASPLAN [42] | 2019 | durva | 182 | 268 | 202 | 268 | 98% | 62% |
 PROLUNG [43] | 2020 | perm+chemo | 17 | 40 | 28 | 40 | NR | NR |
 CheckMate 9LA [44] | 2021 | nivo+ipi+chemo | 138 | 361 | 302 | 361 | 91% | 47% |
 GARNET | 2021 | dostar | 18 | 67 | NR | 67 | NR | NR |
 CHOICE-01 | 2021 | toripa+chemo | 196 | 309 | NR | 309 | NR | NR |
 GEMSTONE-302 | 2021 | sugema+chemo | 203 | 320 | NR | 320 | NR | 64.10% |
 POSEIDON | 2021 | durva+chemo | 137 | 338 | NR | 338 | NR | 44.60% |
durva+treme+chemo | 130 | 338 | NR | 338 | NR | 51.80% | ||
 RATIONAL-303 | 2021 | tisle | 91 | 423 | NR | 423 | NR | 39% |
 CITYCYPE | 2021 | toripa+atezo | 21 | 67 | NR | 67 | NR | 48% |
atezo | 11 | 68 | NR | 68 | NR | 44% | ||
 AFT-16 | 2021 | atezo+chemo+cCRT | 19 | 62 | 48 | 62 | 87.1% | NR |
 PACIFIC [45] | 2019 | durva | 126 | 443 | 359 | 443 | 96.8% | 29.9% |
 KEYNOTE-598 | 2021 | pem | 129 | 284 | 202 | 284 | 68.3% | 19.6% |
pem+ipi | 129 | 284 | 199 | 284 | 76.2% | 35.1% |